Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

Last updated: May 19, 2025
Sponsor: NeuraLight
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

NeuraLight

Clinical Study ID

NCT05862649
NL/PD/2023-1
  • Ages 40-85
  • All Genders

Study Summary

This is a multicenter longitudinal study in about 300 patients with Idiopathic Parkinson's disease, who will be evaluated in several clinical centers with a clinical assessment and an oculometric examination during a time period with specific intervals. This study aims to evaluate the correlation between oculometric measures and clinical assessment over time, as well as the potential to detect early change in clinical status using an oculometric assessment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Men and women with idiopathic PD (Hoehn & Yahr scale 1-2)

  • Age between 40 and 85 years old

  • 0 to 5 years' time since diagnosis

  • Normal or corrected vision

  • Ability to follow instructions

  • Willing and able to sign an informed consent form

  • No anticipated changes in PD medications from baseline throughout the study durationbased on clinical status during screening

  • If treated, stable on treatment for at least 3 months

Exclusion

Exclusion Criteria:

  • Inability to sit for 40 minutes on a chair in a calm manner

  • Personal or 1st degree relative history of epilepsy

  • Additional neurological diseases

  • Drug or alcohol abuse (except for using medical cannabis during 24 hours prior NLexamination date)

  • Pregnancy or a potential pregnancy (self-declaration)

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: NeuraLight
Phase:
Study Start date:
August 21, 2023
Estimated Completion Date:
November 15, 2025

Study Description

This is an multicenter longitudinal study, in about 300 patients with idiopathic PD in several centers. The aim of this study is to evaluate the correlations between oculometric measures and clinical assessment, e.g. the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and the MoCA score over time ,in subjects who meet the inclusion and exclusion criteria, and who provide a signed Informed Consent. In addition, the investigators aim to demonstrate that oculometric measures are able to detect patient deterioration faster than can be detected using the currently available clinical assessment tools. All patients will be assessed over a period of 12 months (5 assessments, at 0, 3, 6, 9, 12 months). During this time period, every subject who consents will undergo a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye- tracking system (Tobii, CE-marked class B approved device) (approx. 30 minutes). The oculometric evaluation will occur for every patient every 3 months. All assessments will be performed during a clinic visit unless authorized to be conducted remotely. During the study, the sponsor will be blinded to the private details of the subjects.

Connect with a study center

  • AIBILI research center

    Coimbra,
    Portugal

    Active - Recruiting

  • Instituto de Biomedicina de Sevilla (IBiS)

    Sevilla,
    Spain

    Active - Recruiting

  • University Hospital Zürich

    Zürich,
    Switzerland

    Site Not Available

  • The VCTC

    Oxford,
    United Kingdom

    Active - Recruiting

  • Rush University

    Chicago, Illinois 60612
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.